Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Breast Neoplasms 4Vomiting 3Neoplasms 3Lymphoma, Non-Hodgkin 3Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Nausea 2Hodgkin Disease 2Hematologic Neoplasms 2Endometrial Neoplasms 2Burkitt Lymphoma 2Uterine Cervical Neoplasms 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Pathologic Complete Response 1Paraproteinemias 1Pain 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1NSCLC 1Mucositis 1Mastocytosis, Systemic 1

Interventions

Dexamethasone 8Bortezomib 7Cyclophosphamide 6Lenalidomide 4isatuximab 3glucarpidase 3Calcium Dobesilate 3Thalidomide 2Kidney Transplantation 2Blood Specimen Collection 2Bendamustine Hydrochloride 2pomalidomide 1gamma-Glutamyl Hydrolase 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Whole-Body Irradiation 1Urination 1Urinalysis 1Stents 1Standard of Care 1Rituximab 1Ranitidine 1Nephrotomy 1Nephrostomy, Percutaneous 1Methotrexate 1Leucovorin 1Ice 1Hematologic Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Renal Insufficiency × Diphenhydramine × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡